Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Adjusted EPS for Q4 was $0.70, surpassing the high-end guidance of $0.66. The FARAPULSE system saw significant adoption, reaching over $1 billion in global revenue in 2024. The WATCHMAN franchise ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...